ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE
Pre-Launchatazanavir sulfate; ritonavir; lamivudine; zidovudine
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing four antiretroviral agents: atazanavir sulfate (protease inhibitor), ritonavir (booster), lamivudine, and zidovudine (both nucleoside reverse transcriptase inhibitors). It is indicated for the treatment of HIV-1 infection in treatment-naive or treatment-experienced patients. The combination works by inhibiting viral protease and reverse transcriptase enzymes, thereby reducing viral replication and delaying disease progression.
Pre-Launch
As a pre-launch product, this combination represents a greenfield opportunity for building brand infrastructure and market positioning in the competitive HIV antiretroviral space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This pre-launch product offers entry-level to mid-career professionals an opportunity to build expertise in HIV therapeutic management and generic/branded combination strategy within a resource-constrained Viatris environment. Career progression will depend on successful market launch execution and ability to differentiate in a mature therapeutic category.
Brand Manager
Worked on ATAZANAVIR SULFATE;RITONAVIR;LAMIVUDINE;ZIDOVUDINE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.